Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02436772 · ClinicalTrials.gov registry record

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

A clinical trial, sponsored by SCRI Development Innovations.

Completed
Registry status
74
Enrollment target

NCT02436772: Completed study, sponsored by SCRI Development Innovations.

NCT02436772 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02436772 has completed, sponsored by SCRI Development Innovations.

COMPLETED
Registry status
74 participants
Enrollment target

Study Summary

This study evaluates the performance of a blood test for detecting biomarkers in metastatic breast cancer patients at one clinic against standard testing.

Primary Outcome

determined by the comparison between OncoCEE test and conventional test

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2015-05-13
Est. Completion 2017-07-07
SCRI Development Innovations

146 total trials

What the finished NCT02436772 record still lists

NCT02436772 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 74 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT02436772 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02436772 about?

NCT02436772 is a clinical study titled "Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC". This study evaluates the performance of a blood test for detecting biomarkers in metastatic breast cancer patients at one clinic against standard testing.

What is the current status of trial NCT02436772?

This trial is currently completed. The enrollment target is 74 participants. The study started on 2015-05-13. Estimated completion is 2017-07-07.

Who is sponsoring clinical trial NCT02436772?

This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02436772, the US trial registry maintained by the National Library of Medicine. NCT02436772 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.